News

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...
Interdisciplinary GU Cancer Forum 2025, urothelial carcinoma, Metastatic Urothelial Carcinoma, enfortumab vedotin, advanced urothelial carcinoma when enfortumab vedotin, Optimal Sequence of Treatment ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating ...
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Verona Pharma surged by 20.62 percent on Wednesday to end at $104.77 per share following news that it was being acquired by US-based pharmaceutical company Merck for $10 billion.
Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
Raleigh’s Verona Pharma acquired by Merck for $10 billion as maker of COPD treatment Ohtuvayre merges with pharmaceutical company with growing Durham, NC footprint ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma’s new ch… ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.